Li Minmin, Chen Tao, Hua Zhongqiu, Yan Hong, Wang Duolao, Li Zhaoqing, Kang Yijun, Zhu Ni, Li Chao
Shaanxi Provincial Center for Disease Control and Prevention, No. 3 East Jian Road, PO Box 46, Xi'an, 710041, Shaanxi, People's Republic of China.
Department of Clinical Sciences, Liverpool School of Tropical Medicine Pembroke Place, Liverpool, UK.
Diabetol Metab Syndr. 2021 Oct 30;13(1):127. doi: 10.1186/s13098-021-00743-3.
Both pulmonary tuberculosis (PTB) and diabetes mellitus (DM) are major global public health problems. We estimated the global, regional, and national prevalence of diabetes mellitus in a population with PTB.
We searched for observational studies of DM in people with PTB using the PubMed and Embase electronic bibliographic databases, focusing on articles published in the English language from database inception until March 31, 2021. We included original research that reported the prevalence of DM in PTB or those that had sufficient data to compute these estimates. Studies were excluded if they did not provide primary data or were case studies or reviews. Two authors independently extracted the articles and collected detailed information using a predefined questionnaire. A country-specific random-effects meta-analysis was used for countries with two or more available studies, and a fractional response regression model was employed to predict the prevalence of DM in PTB for countries with one or no study. The study was registered with the International Prospective Register of Systematic Reviews, using the registration number CRD42018101989.
We identified 22,658 studies, and 153, across 51 countries, were retained for data extraction. The global prevalence of DM among patients with PTB was estimated to be 13.73% (95% confidence interval [CI] 12.51-14.95). The prevalence rates were 19.32% (95% CI 13.18-25.46) in the region of the Americas, 17.31% (95% CI 12.48-22.14) in the European region, 14.62% (95% CI 12.05-17.18) in Southeast Asia, 13.59% (95% CI 7.24-19.95) in the western Pacific region, 9.61% (95% CI 4.55-14.68) in the eastern Mediterranean region, and 9.30% (95% CI 2.83-15.76) in the African region. The country with the highest estimated prevalence was the Marshall Islands (50.12%; 95% CI 4.28-95.76).
Comorbid PTB and DM remain prevalent worldwide.
肺结核（PTB）和糖尿病（DM）都是全球主要的公共卫生问题。我们估计了肺结核患者中糖尿病的全球、区域和国家患病率。
我们使用PubMed和Embase电子文献数据库搜索了关于肺结核患者糖尿病的观察性研究，重点关注从数据库建立到2021年3月31日以英文发表的文章。我们纳入了报告肺结核患者糖尿病患病率或有足够数据计算这些估计值的原始研究。如果研究未提供原始数据或为病例研究或综述，则将其排除。两位作者独立提取文章并使用预定义问卷收集详细信息。对于有两项或更多可用研究的国家，采用特定国家的随机效应荟萃分析；对于有一项或没有研究的国家，采用分数响应回归模型预测肺结核患者中糖尿病的患病率。该研究已在国际前瞻性系统评价注册库注册，注册号为CRD42018101989。
我们识别出22658项研究，来自51个国家的153项研究被保留用于数据提取。肺结核患者中糖尿病的全球患病率估计为13.73%（95%置信区间[CI]12.51 - 14.95）。美洲地区的患病率为19.32%（95%CI 13.18 - 25.46），欧洲地区为17.31%（95%CI 12.48 - 22.14），东南亚为14.62%（95%CI 12.05 - 17.18），西太平洋地区为13.59%（95%CI 7.24 - 19.95），东地中海地区为9.61%（95%CI 4.55 - 14.68），非洲地区为9.30%（95%CI 2.83 - 15.76）。估计患病率最高的国家是马绍尔群岛（50.12%；95%CI 4.28 - 95.76）。
肺结核和糖尿病合并症在全球范围内仍然普遍存在。
